Annals of Oncology 14:1442-1448, 2003
© 2003 European Society for Medical Oncology
Original Paper |
Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study
1 Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen Medical School, Essen; 2 Aventis, Department of Clinical Research, Oncology, Bad Soden, Germany; 3 Hoffmann-La Roche, Nutely, NJ; 4 Department of Molecular Pharmacology and Experimental Therapeutics, Grace Cancer Drug Center, Roswell Park Cancer Institute, Buffalo, NY, USA
Received 11 March 2003; revised 3 May 2003; accepted 3 June 2003
Background:
To define the maximum-tolerated dose (MTD) and to evaluate the dose-limiting toxicities (DLTs) of the combination of capecitabine and irinotecan in patients with metastatic colorectal cancer.
Patients and methods:
Thirty-seven patients with measurable metastatic colorectal cancer with no prior chemotherapy for metastatic disease were treated at three dose levels (DLs). For the first two dose levels, irinotecan (70 mg/m2) was administered once a week for 6 weeks in combination with 2 weeks of capecitabine at 1000 mg/m2 (DL1) or 1250 mg/m2 (DL2) twice daily, starting on days 1 and 22. In the last dose escalation step, the dose of irinotecan was increased to 80 mg/m2 (DL3). One cycle lasted 7 weeks.
Results:
In the subsequent phase I trial, 96 cycles of capecitabine and irinotecan were administered. At DL3, three out of six patients experienced DLTs (diarrhea, neutropenia, asthenia). In order to confirm the safety of the recommended dose, DL2 was extended to 15 patients. Five patients (33%) showed DLTs at this dose level, which was considered too high to embark on further clinical studies. Subsequently, the starting dose (DL1) was extended to a total of 16 patients, with diarrhea being the main toxicity. The overall response rate was 38% [95% confidence interval (CI) 21% to 58%], with a median response duration of 8.7 months (95% CI 6.4–11.5 months).
Conclusions:
The recommended doses for further studies are irinotecan 70 mg/m2 and capecitabine 1000 mg/m2. The combination of capecitabine and irinotecan appears to have significant therapeutic efficacy with manageable toxicity.
Key words: capecitabine, colorectal cancer, irinotecan, phase I study
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Q. Sun, M. Hang, W. Xu, W. Mao, X. Hang, M. Li, and J. Zhang Irinotecan Plus Capecitabine as a Second-line Treatment after Failure of 5-Fluorouracil and Platinum in Patients with Advanced Gastric Cancer Jpn. J. Clin. Oncol., October 1, 2009; (2009) hyp116v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zhao, J. Zhu, X. Ji, J. Cai, F. Wan, Q. Li, B. Zhong, S. Tucker, and D. Wang A Phase II Study of Irinotecan and Capecitabine for Patients with Unresectable Liver-only Metastases from Colorectal Cancer Jpn. J. Clin. Oncol., September 22, 2009; (2009) hyp114v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. KOLINSKY, Y.-E ZHANG, U. DUGAN, D. HEIMBROOK, K. PACKMAN, and B. HIGGINS Novel Regimens of Capecitabine Alone and Combined with Irinotecan and Bevacizumab in Colorectal Cancer Xenografts Anticancer Res, January 1, 2009; 29(1): 91 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. O'Neil and H. L. McLeod Thymidine Phosphorylase and Capecitabine: A Predictive Marker for Therapy Selection? J. Clin. Oncol., September 1, 2006; 24(25): 4051 - 4053. [Full Text] [PDF]
|
|
|
|
|
|
I. Hyodo, K. Shirao, T. Doi, K. Hatake, Y. Arai, K. Yamaguchi, T. Tamura, S. Takemiya, H. Takiuchi, K. Nakagawa, et al. A Phase II Study of the Global Dose and Schedule of Capecitabine in Japanese Patients with Metastatic Colorectal Cancer Jpn. J. Clin. Oncol., July 1, 2006; 36(7): 410 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. E.L.M. Kuppens, E. Dansin, H. Boot, C. Feger, S. Assadourian, M.-E. Bonneterre, J. H. Beijnen, J. H.M. Schellens, and J. Bonneterre Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. Clin. Cancer Res., June 15, 2006; 12(12): 3774 - 3781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kelly and R. M. Goldberg Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence J. Clin. Oncol., July 10, 2005; 23(20): 4553 - 4560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.P. Kalofonos, G. Aravantinos, P. Kosmidis, P. Papakostas, T. Economopoulos, M. Dimopoulos, D. Skarlos, A. Bamias, D. Pectasides, S. Chalkidou, et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study Ann. Onc., June 1, 2005; 16(6): 869 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.-D. Hofheinz, B. von Gerstenberg-Helldorf, F. Wenz, U. Gnad, U. Kraus-Tiefenbacher, A. Muldner, R. Hehlmann, S. Post, A. Hochhaus, and F. Willeke Phase I Trial of Capecitabine and Weekly Irinotecan in Combination With Radiotherapy for Neoadjuvant Therapy of Rectal Cancer J. Clin. Oncol., March 1, 2005; 23(7): 1350 - 1357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Borner, J. Bernhard, D. Dietrich, R. Popescu, M. Wernli, P. Saletti, D. Rauch, R. Herrmann, D. Koeberle, H. Honegger, et al. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity Ann. Onc., February 1, 2005; 16(2): 282 - 288. [Abstract] [Full Text] [PDF]
|
|